ES2344989T3 - Analogos de 17,20(e)-deshidro vitamina d y sus usos. - Google Patents

Analogos de 17,20(e)-deshidro vitamina d y sus usos. Download PDF

Info

Publication number
ES2344989T3
ES2344989T3 ES05851757T ES05851757T ES2344989T3 ES 2344989 T3 ES2344989 T3 ES 2344989T3 ES 05851757 T ES05851757 T ES 05851757T ES 05851757 T ES05851757 T ES 05851757T ES 2344989 T3 ES2344989 T3 ES 2344989T3
Authority
ES
Spain
Prior art keywords
group
hydroxy
hydrogen
represent
baselineskip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05851757T
Other languages
English (en)
Spanish (es)
Inventor
Hector F. Deluca
Bulli Padmaja Tadi
Lori A. Plum
Margaret Clagett-Dame
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2344989T3 publication Critical patent/ES2344989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
ES05851757T 2004-11-22 2005-11-18 Analogos de 17,20(e)-deshidro vitamina d y sus usos. Expired - Lifetime ES2344989T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63000704P 2004-11-22 2004-11-22
US630007P 2004-11-22

Publications (1)

Publication Number Publication Date
ES2344989T3 true ES2344989T3 (es) 2010-09-13

Family

ID=36216285

Family Applications (3)

Application Number Title Priority Date Filing Date
ES05851757T Expired - Lifetime ES2344989T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(e)-deshidro vitamina d y sus usos.
ES05849730T Expired - Lifetime ES2346774T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(z)-deshidro vtamina d y sus usos.
ES05851805T Expired - Lifetime ES2347058T3 (es) 2004-11-22 2005-11-18 2-metilen-19-nor-1(alfha)-hydroxy-17-eno-hemopregnacalciferol y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES05849730T Expired - Lifetime ES2346774T3 (es) 2004-11-22 2005-11-18 Analogos de 17,20(z)-deshidro vtamina d y sus usos.
ES05851805T Expired - Lifetime ES2347058T3 (es) 2004-11-22 2005-11-18 2-metilen-19-nor-1(alfha)-hydroxy-17-eno-hemopregnacalciferol y sus usos.

Country Status (11)

Country Link
US (6) US7241752B2 (enExample)
EP (3) EP1828114B1 (enExample)
JP (3) JP5161582B2 (enExample)
AT (3) ATE469127T1 (enExample)
AU (3) AU2005309806B2 (enExample)
CA (3) CA2588410C (enExample)
DE (3) DE602005020842D1 (enExample)
ES (3) ES2344989T3 (enExample)
MX (3) MX2007006546A (enExample)
NZ (3) NZ555282A (enExample)
WO (3) WO2006057900A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
DE602005020842D1 (de) * 2004-11-22 2010-06-02 Wisconsin Alumni Res Found 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen
US7244719B2 (en) * 2004-11-22 2007-07-17 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
CA2676512A1 (en) * 2007-01-25 2008-07-31 Bioxell S.P.A. Synthesis of 1.alpha.-fluoro-25-hydroxy-16-23e-diene-26,27-bishomo-20-epi-cholecalciferol
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
US20120237472A1 (en) * 2009-07-24 2012-09-20 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
MX2012003883A (es) * 2009-10-02 2012-06-27 Wisconsin Alumni Res Found Analogos de (20s,22e)-2-metileno-19-nor-22-ene-1a,25-dihidroxovita mina d3.
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
US8410080B1 (en) * 2011-10-21 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
US5362719A (en) 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
DE69016014T2 (de) 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
GB9214202D0 (en) 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
ATE178596T1 (de) 1994-12-14 1999-04-15 Duphar Int Res Vitamin-d-derivate und verfahren zur herstellung dieser verbindungen
GB9625271D0 (en) * 1996-12-04 1997-01-22 Leo Pharm Prod Ltd Chemical compounds
NZ336924A (en) * 1997-02-13 2001-06-29 Bone Care Int Inc Targeted therapeutic delivery of vitamin D compounds via a Vitamin D conjugate
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
CN1090180C (zh) 1997-06-25 2002-09-04 帝人株式会社 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂
GB9721156D0 (en) 1997-10-06 1997-12-03 Leo Pharm Prod Ltd Novel vitamin d analogues
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
ES2309069T3 (es) * 2000-05-31 2008-12-16 Wisconsin Alumni Research Foundation Compuestos de 2-etil y 2-etiliden-19-nor-vitamina d.
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
EP1392323B1 (en) 2001-05-22 2008-10-08 Bioxell S.p.a. Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
HK1079766B (zh) * 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
CA2544502A1 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
WO2005051396A2 (en) 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
WO2006057884A2 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
DE602005020842D1 (de) * 2004-11-22 2010-06-02 Wisconsin Alumni Res Found 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen
MX2008012673A (es) 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-19, 21-dinorvitamina d3 y sus usos.
CA2683628C (en) * 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency

Also Published As

Publication number Publication date
US20070249569A1 (en) 2007-10-25
DE602005020842D1 (de) 2010-06-02
DE602005021538D1 (de) 2010-07-08
EP1846370B1 (en) 2010-06-02
EP1828114B1 (en) 2010-04-21
NZ555282A (en) 2010-12-24
US7241750B2 (en) 2007-07-10
AU2005309806A1 (en) 2006-06-01
CA2588401C (en) 2013-02-12
WO2006057900A3 (en) 2006-07-06
MX2007006262A (es) 2007-07-10
US20060116351A1 (en) 2006-06-01
NZ555277A (en) 2010-12-24
JP5161582B2 (ja) 2013-03-13
EP1828114A2 (en) 2007-09-05
US20060111330A1 (en) 2006-05-25
US7741313B2 (en) 2010-06-22
US20070249568A1 (en) 2007-10-25
AU2005309790A1 (en) 2006-06-01
CA2588410A1 (en) 2006-06-01
AU2005309805A1 (en) 2006-06-01
ATE469127T1 (de) 2010-06-15
MX2007006546A (es) 2007-08-17
US7241748B2 (en) 2007-07-10
CA2588396A1 (en) 2006-06-01
WO2006057901A3 (en) 2006-07-13
US20070259838A1 (en) 2007-11-08
ATE469883T1 (de) 2010-06-15
JP2008520690A (ja) 2008-06-19
ES2346774T3 (es) 2010-10-20
JP2008520704A (ja) 2008-06-19
US8232263B2 (en) 2012-07-31
AU2005309790B2 (en) 2012-03-08
ES2347058T3 (es) 2010-10-25
AU2005309806B2 (en) 2012-03-08
JP5043673B2 (ja) 2012-10-10
EP1846370A2 (en) 2007-10-24
CA2588401A1 (en) 2006-06-01
NZ555278A (en) 2010-12-24
DE602005021702D1 (de) 2010-07-15
WO2006057900A2 (en) 2006-06-01
AU2005309805B2 (en) 2011-06-09
US7241752B2 (en) 2007-07-10
ATE465144T1 (de) 2010-05-15
US20060111321A1 (en) 2006-05-25
US7704982B2 (en) 2010-04-27
CA2588396C (en) 2013-04-23
CA2588410C (en) 2013-04-02
JP2008520705A (ja) 2008-06-19
EP1817279B1 (en) 2010-05-26
WO2006057885A2 (en) 2006-06-01
WO2006057901A2 (en) 2006-06-01
WO2006057885A3 (en) 2006-06-29
MX2007006261A (es) 2007-07-10
EP1817279A2 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
ES2339401T3 (es) Analogo de vitamina d-nel, metodos y usos del mismo.
ES2339402T3 (es) Analogo de vitamina d - rak, metodos y usos del mismo.
ES2274116T3 (es) 1-alfa-hidroxi-2-metilenj-19-nor-pregnacalciferol y sus usos.
ES2206893T3 (es) Compuestos de 2-alquil-19-nor-vitamina d.
ES2227215T3 (es) 1 alfa-hidroxi.2.metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.
ES2291305T3 (es) Compuestos 2-alquiliden-19-nor-vitamina d y sus usos terapeuticos.
US7741313B2 (en) 17,20(E)-dehydro vitamin D analogs and their uses
ES2420682T3 (es) Compuestos tipo 26,27-homologada-20-epi-2-alquil-19-nor-vitamina D
MX2008012912A (es) Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos.
ES2387714T3 (es) Análogos de 2-metilen-20-metil-19,24,25,26,27-pentanor-vitamina D
MX2010007266A (es) Análogos de vitamina d, (20s)-23, 23-difluoro-2-metilen-19-nor-bis homopregnacalciferol.
ES2404061T3 (es) 2-Metileno-19-nor-(20S-24S)-1-alfa,25-dihidroxivitamina-D2
ES2545403T3 (es) (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3
ES2349662T3 (es) 2-metileno-18,19-dinor-1alfa-hidroxi-homopregnacalciferol y sus usos.
MX2008012671A (es) Analogos 1 a,25-dihidroxi- 19, 26,27-trinor vitamina d 2-sustituidos y sus usos.
ES2236830T3 (es) Derivados de la vitamina d3.
AU2009268508A1 (en) 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
ES2277293T3 (es) 2-metilen-19-nor-20(s)-25-metil-1-alfa-hidroxicalciferol y sus usos.
ES2358914T3 (es) 2-metileno-19,21-dinor-1alfa-hidroxi-bishomopregnacalciferol.
US8754067B2 (en) 22-haloacetoxy-homopregnacalciferol analogs and their uses